Antibiotic shield tested for blood cancer patients
NCT ID NCT03594149
First seen Jan 04, 2026 · Last updated Jun 21, 2026 · Updated 21 times
Summary
This study tested whether the antibiotic levofloxacin can prevent serious fevers and infections in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who are receiving a treatment called azacitidine. The trial enrolled 60 adults and compared those who took daily levofloxacin to those who did not. The goal was to see if the antibiotic could reduce the number of febrile episodes requiring hospitalization.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU Lille
Lille, 59037, France
-
CHU Amiens
Amiens, 80000, France
-
CHU Caen
Caen, 14033, France
-
Centre Henri Becquerel
Rouen, 76000, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Levofloxacin (an antibiotic)
What this could lead to
If it works, this could provide a standard way to prevent dangerous infections in people with MDS or AML undergoing treatment.
What could go wrong
This is a small, completed trial with only 60 participants. Results may not apply to all patients, and overuse of antibiotics can lead to drug-resistant bacteria.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.